Concord Medical Services Holdings Limited CCM
Company Overview
Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, and helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, China.
Why Investors Should Care
Net profit has compounded at 27.0% per year over the last five years.
Recent Developments
- Dec 2025 Revenue of $460.51M (+19.9% YoY); net profit $-92.81M.
- Trailing 12 Months Year-on-year growth — revenue +57.4%.
- 5-Year Trend Long-term compounding — revenue CAGR -0.8%, profit CAGR 27.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -0.82% |
| 1 Year: | 57.40% |
Compounded Profit Growth
| 5 Years: | 27.02% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -7.78% |
| 6 Months: | +24.62% |
| 3 Months: | +0.21% |
| 1 Month: | +1.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.06 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 27.0% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -0.8% CAGR over 5 years.
- Trading 29.6% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CCM Concord Medical Services Holdings Limited | 4.86 | -1.54 | $21.10M | 0.00% | -4.81% | -21.88% | -0.82% | 27.02% |
| 2 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 3 | WAT Waters Corporation SPX | 400.00 | 50.96 | $39.27B | 0.00% | 20.92% | 5.21% | 4.60% | 2.80% |
| 4 | ZTS Zoetis Inc. SPX | 74.39 | 12.20 | $31.19B | 2.74% | 27.18% | 67.75% | 5.92% | 18.61% |
| 5 | ZBH Zimmer Biomet Holdings, Inc. SPX | 98.16 | 25.43 | $18.99B | 1.02% | 6.61% | 6.07% | 4.50% | -0.54% |
| 6 | BTSG BrightSpring Health Services, Inc. R2K | 59.71 | 77.55 | $11.72B | 0.00% | 6.47% | 9.23% | 18.69% | - |
| 7 | NUVL Nuvalent, Inc. R2K | 123.96 | -20.46 | $9.12B | 0.00% | -31.35% | -41.19% | - | - |
| 8 | IBRX ImmunityBio, Inc. R2K | 7.17 | -8.44 | $7.51B | 0.00% | -58.17% | 70.21% | 54.76% | - |
| 9 | BLTE Belite Bio, Inc | 158.50 | -62.16 | $6.35B | 0.00% | -10.07% | -18.93% | - | -171.21% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 472.08M | 537.40M | 383.96M | 460.51M |
| Cost of Revenue | - | 624.49M | 614.01M | 463.12M | 434.69M |
| Gross Profit | - | -152.41M | -76.61M | -79.16M | 25.82M |
| Operating Expenses | - | 372.64M | 386.38M | 453.00M | 265.15M |
| Operating Income | - | -525.05M | -462.99M | -532.16M | -239.33M |
| EBITDA | - | -586.73M | -261.47M | -345.62M | -71.77M |
| Interest Expense | - | 120.36M | 165.67M | 193.20M | 152.33M |
| Pretax Income | - | -839.90M | -555.59M | -669.58M | -373.36M |
| Tax Provision | - | -70.91M | -24.57M | -17.50M | 6.06M |
| Net Income | - | -489.66M | -297.66M | -308.24M | -92.81M |
| Diluted EPS | -187.80 | -112.20 | -68.10 | -70.50 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 6.00B | 6.05B | 6.73B | 6.55B |
| Current Assets | - | 759.80M | 617.21M | 983.97M | 941.91M |
| Cash & Equivalents | - | 158.28M | 58.14M | 216.22M | 297.79M |
| Inventory | - | 84.83M | 40.35M | 33.44M | 45.97M |
| Receivables | - | 130.27M | 73.50M | 51.17M | 44.05M |
| Total Liabilities | - | 3.99B | 4.31B | 5.11B | 4.70B |
| Current Liabilities | - | 1.12B | 1.95B | 2.13B | 1.95B |
| Long Term Debt | - | 2.49B | 2.01B | 2.71B | 2.49B |
| Total Debt | - | 3.24B | 3.30B | 3.93B | 3.63B |
| Total Equity | - | -1.86B | -2.12B | -2.28B | -2.10B |
| Shares Outstanding | - | 142.35M | 142.35M | 142.35M | 142.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -216.69M | -276.47M | -397.75M | -201.82M |
| Investing Cash Flow | - | -118.79M | -47.68M | -593.44M | 53.97M |
| Financing Cash Flow | - | 383.09M | 257.65M | 1.15B | 197.23M |
| Capital Expenditure | - | -384.81M | -119.91M | -410.83M | -91.33M |
| Free Cash Flow | - | -601.50M | -396.38M | -808.58M | -293.16M |
| Net Change in Cash | - | 47.60M | -66.50M | 154.84M | 49.37M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | -32.3% | -14.3% | -20.6% | 5.6% |
| Operating Margin % | - | -111.2% | -86.2% | -138.6% | -52.0% |
| Net Margin % | - | -103.7% | -55.4% | -80.3% | -20.2% |
| ROE % | - | 26.3% | 14.0% | 13.5% | 4.4% |
| ROCE % | - | -10.8% | -11.3% | -11.6% | -5.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP | 0.42% | 11.72K | $56.97K |
| 2 | UBS Group AG | 0.02% | 615 | $2.99K |
| 3 | Morgan Stanley | - | 100 | $486 |
| 4 | SBI Securities Co., Ltd. | - | 4 | $19 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CCM
TWO Announces Third Quarter 2026 Stub Period Dividend on Common Stock - Business Wire
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQQkl1YlpXVW5keWNpMjBuVUs0cHltT3pqUmpWbnZ0cm8yV0ZzTEtQX0xJY1EtRENFbmRSajNjLW9JMmo4MURvME9TeXFZS1dIejlWOFJnV3JmWjE0OEY4ME95XzF1UUVGaEQxZnd2XzY3X3BYYkxYbTlqTUsxdjNOaU1FdHowdGhwbXpqam…
CCM|Concord Medical Services Holdings Ltd|Price:4.300|Chg%:-0.350 - TradingKey
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1sU1JuVy1rU21NT19kWXJfT1oxbHF3QmRlSkdLQ18xTFFLc1JVTGRLNlJrOVQ2QTZsV0poakhLVy1rSThuMTE4TThqczZUaXZmMzVldzFWWXg?oc=5" target="_blank">CCM|Concord Medical Services Holdings Ltd|Price:…
Two Harbors adjourns vote on CCM sale to July 2 - HousingWire
<a href="https://news.google.com/rss/articles/CBMickFVX3lxTFAyRmZLSHpXcW1kb3o1SkdWRF8zaVhPUjhDYUg4RG9YYVB3V2xJemhsb1FNWVRvbzdsMFpmZWdmdzVpU2Q4ZVlTbWdEdERsM1dIem1sdktCVlRXckxEMWtLWGZ2RS1KVGI4RGw5ZmNTc2FZZw?oc=5" target="_blank">Two Harbors a…
Two Harbors delays shareholder vote on $12 cash sale to CCM - Stock Titan
<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPMzN5bVpDbG5WX1MzcGdUcmVHOVAyYU9BNkJ1SU56Z0xTSjM0VV9fNW4xd3l3cmxZajFmcGp5WjRKbndYMllRakVpU0dRcUk2NGVqcEl1cktuTENONlF0emxjcTJ2OXhlS2w0dWdiT0lmQy1uNHJVM1lPak90emQ4b2dZT3RLUkFxVU9Cd1…
Two Harbors board rebuffs sweetened UWM bid, backs CrossCountry deal - mpamag.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNLUNqeDFXdzd6WGstR0lNOGk0TUNocEhzTFVNOVJMbGRlZlo1OFlUZGRjM3ZwVWo5dElwZVFUNDMxbjlydm5mNDVxcmJNWFFoX1g2eTZxTFZIa0JEVW42WlFlLTA3TUZYNXctclkwM3M0elhuRlZzWUh0N3RpVGgtTXFBQlVWcENIa0w3Vz…
Insider Sale: Vice Chair of CCM of $CSL Sells 1,500 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxNU1dGMDdOeUNGSV9zMUd6eGMwNFBhTHhhUF9LRm13cXktTC10TmZzR0UwcUZfckpnSE13NDFpVTlfa1BOdm1OOTJfeE1Bd2tXdmpsRHFTTjJBdXQyNHVjN05RdzhLaXJnbXJ6VW82RlZGdUUzTU1MbDhxcGxpeHZZX0JGeG9ZU2oyWGE0eH…
CCM — Frequently Asked Questions
What is the current share price of Concord Medical Services Holdings Limited (CCM)?
As of 2026-08-05 17:25 PDT, Concord Medical Services Holdings Limited (CCM) trades at $4.86 on NYSE. Its 52-week range is $3.43 to $6.90.
What is the market capitalisation of CCM?
Concord Medical Services Holdings Limited (CCM) has a market capitalisation of $21.10M on NYSE.
What is the P/E ratio of CCM?
CCM trades at a trailing price-to-earnings (P/E) ratio of -1.54. The industry average P/E is 25.51. Its price-to-book (P/B) ratio is -0.07.
What is the return on equity (ROE) of CCM?
CCM has a return on equity (ROE) of -21.88%. Its return on capital employed (ROCE) is -4.81%.
Is CCM a good stock to buy?
This page provides a data-driven analysis of Concord Medical Services Holdings Limited (CCM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.